I can’t talk enough about how important
it is to take care of your skin. Dry, oily, sensitive, no matter what your skin
type, it’s important to research and talk to a skincare specialist about the
right skincare regime for you.
Personally, I have dry, sensitive skin,
and I’m also prone to rosacea. Yesterday I posted about Mirvaso (brimonidine)
topical gel, 0.33%, a new topical gel specifically developed and indicated to treat
the persistent facial redness of rosacea. Mirvaso is all about treating the redness, so you don’t have
to conceal with makeup.
The Break Up with Your Makeup portal,
which you can get to from yesterday’s post, includes information
on skincare tips and the treatment for rosacea. You can also enter for a chance
to win a trip to the Emmys! Enter by adding your email address into the portal
and clicking ‘Submit.’
If you miss the window for entering the
trip, don’t fret. Galderma, who also makes Cetaphil, has generously offered to
give one lucky Lipgloss Break reader a Cetaphil Gift Basket! Enter below!
***Giveaway***
Enter for a chance to win a Cetaphil Gift Basket!
Fill out the form below to win! There are also several different ways you can get extra entries: sign up for my mailing list, post a link to this giveaway on your blog, follow my blog, follow me & retweet on Twitter , follow me on Pinterest, add me to one of your Google+ circles, follow me on Instagram or become a fan on Facebook. Make sure to list the number of extra entries in the form below. Enter up to once a day to increase your chances of winning!
This giveaway is open to US residents only. The contest will end on Thursday, July 31. I will randomly select a winner and announce them on Lipgloss Break, so keep checking to see if you're a winner - Good Luck!
Note:
This post is sponsored by Galderma Laboratories, L.P. Please click here for more
information regarding my disclaimer.
Important Safety Information
Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
You are encouraged to report
negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*Each gram of gel contains 5 mg
of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.
